{"prompt": "[\"Patients who, by the investigator's assessment, cannot tolerate pertuzumab and\", 'trastuzumab FDC SC or P+H IV may be allowed to receive P+H IV or pertuzumab and', 'trastuzumab FDC SC, respectively, for their remaining planned anti-HER2 treatment cycles.', 'The investigator must obtain approval from the Medical Monitor to switch study treatment.', 'Patient preference will be assessed based on the PPQ (administered following treatment', 'administration on Day 1, Cycle 6 of the Treatment Cross-over Period). Treatment', 'satisfaction will be assessed based on the TASQ (administered following treatment', 'administration on Day 1 of Cycles 3 and 6 of the Treatment Cross-over Period). Healthcare', 'professionals will record their perception of time/resource use and convenience of treatment', 'administration completing the HCPQs. Perception of time use will be captured during the', 'Treatment Cross-over Period and perception of convenience will be captured after', \"administration of each patient's treatment Cycle 6. Health-related quality of life will be\", 'assessed based on EORTC QLQ-C30 completed at baseline, Cycle 3, Cycle 6, and the end', 'of study treatment visits, as well as at 18 months, 2 years, and 3 years from randomization.', 'The study questionnaires are provided in Appendix 2 and Appendix 3.', 'Patients will be assessed for safety by regular evaluation of AEs, vital signs, routine clinical', 'laboratory tests (haematology, blood chemistry) and LVEF assessments; and by physical', 'examinations. Adverse events will be reported and graded according to the NCI CTCAE v4.0.', 'Efficacy will be assessed based on investigator-evaluated disease status determined', 'according to assessments conducted per institutional practice or according to the American', 'Cancer Society / American Society of Clinical Oncology Breast Cancer (ACS/ASCO) Breast', 'Cancer Survivorship Care Guideline [Runowicz et al. 2016, see Appendix 4].', 'Patients will undergo an End of Treatment Visit approximately 28 days after completing', 'study treatment and will enter the Follow-up Period wherein they will be followed for disease', 'status, survival and HRQoL (via the EORTC QLQ-C30) for 3 years from the date the last', 'patient is randomized. The study Schedule of Activities is provided in Appendix 1.', 'Approximately 140 patients from approximately 42 study sites worldwide will be randomized', 'in the study. Patients who withdraw from the study following randomization will not be', 'replaced. Patients can be screened for the study more than once.', '3.2', 'END OF STUDY AND LENGTH OF STUDY', 'The end of the study is defined the Last Patient, Last Visit (LPLV) which will occur three', 'years after the last patient is randomized or the date at which the last data point required for', 'the final statistical analysis or safety follow-up is received from the last patient, whichever', 'occurs later.', 'In addition, the Sponsor may decide to terminate the study at any time.', 'The study is estimated to last approximately 4 years, based on a recruitment period of up to', '10 months and 3 years of follow-up after the last patient is randomized.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '39 / Protocol MO40628, Version 12']['3.3', 'RATIONALE FOR STUDY DESIGN', '3.3.1', 'Rationale for Perjeta IV, Herceptin IV, and Pertuzumab and Trastuzumab', 'FDC SC Doses and Schedules', 'Perjeta IV and Herceptin IV loading and maintenance doses in the study are the approved', 'doses for the treatment of EBC.', 'Pertuzumab and trastuzumab FDC SC maintenance and loading doses in the study are', 'based on the approved dose of Herceptin SC (600 mg Herceptin with no loading dose', 'required), clinical studies of pertuzumab showing similar Ctrough and AUC with pertuzumab', 'SC 600 mg and Perjeta IV 420 mg (Study BO30185), and dose proportionality of', 'pertuzumab 1200 mg SC confirmed through PK linearity (see Section 1.2.4).', 'Both the loading and maintenance doses of pertuzumab and trastuzumab FDC SC include', '2000 U/mL rHuPH20. The concentration of this excipient is the same as in the approved', 'Herceptin SC formulation and has been tested in the aforementioned Study BO30185 (see', 'Section 1.2.4).', 'The scheduling of all IMPs (every 3 weeks with loading doses required if 6 weeks since', 'last administration of HER2-targeted therapy) are based on PK studies comparing IV and SC', 'administrations of each molecule (Study BO22227, Study BO30185) and the approved', 'scheduling for Perjeta IV, Herceptin IV and Herceptin SC.', '3.3.2', 'Rationale for Patient Population', 'Early breast cancer patients who have received neoadjuvant Perjeta IV and Herceptin and', 'have completed neoadjuvant chemotherapy and subsequently undergone surgery for their', 'breast cancer were selected as the target population for this study since continued dual', 'HER2+ blockade with Perjeta and Herceptin is standard of care in these patients. The', 'completion of chemotherapy prior to study entry limits the influence of chemotherapy', 'administrations and related toxicity on study endpoints. Patients will be allowed to receive', 'adjuvant radiotherapy and/or hormone therapy during the study as these treatments will be', 'indicated in some cases.', '3.3.3', 'Rationale for Randomization Stratification Factors', 'To include as wide a population as possible while limiting imbalances that may affect study', 'outcomes, randomization will be stratified. Since neoadjuvant treatment selections are', 'associated with varying toxicities and disease outcomes, randomization will be stratified for', 'neoadjuvant chemotherapy regimen (anthracyclines + taxanes VS. carboplatin + taxanes VS.', 'taxanes only).', 'Randomization will also be stratified for neoadjuvant treatment response (pCR VS. non-pCR)', 'and hormone receptor status (positive vs. negative) due to the associations of these factors', 'with disease outcomes. Complete pathological response to neoadjuvant treatment has been', 'shown to predict for improved disease outcomes in HER2+ EBC [Gianni et al. 2016].', 'Differences in treatment response with hormone receptor status have also been shown in', 'HER2+ EBC trials of Herceptin and P+H IV [Cameron et al. 2017; Study BO25126 - see', \"Perjeta Investigator's Brochure 2018].\", 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '40 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}